American Association of Individual Investors1d
Which Is a Better Investment, Corcept Therapeutics Incorporated or Sanofi Stock?
Learn more about whether Corcept Therapeutics Incorporated or Sanofi is a better investment based on AAII's A+ Investor ...
PharmiWeb2d
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
Medical Dialogues4d
USFDA approves Sanofi Qfitlia for hemophilia A or B with or without inhibitors
Paris: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia ...
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
Finanznachrichten5d
Sanofi Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Brian Foard Executive Vice President, Head of Specialty Care, Sanofi "This approval highlights our commitment to advancing innovation and improving care for the rare blood disorders community. Qfitlia ...
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...
PharmiWeb5d
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Medical Dialogues6d
Sanofi gets USFDA fast track designation for Chlamydia vaccine candidate
Paris: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate ...
Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...
PipelineReview.com7d
Chlamydia vaccine candidate granted fast track designation by the US FDA
PARIS, France I March 26, 2025 I The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention ...